![Kerry Russell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Storia della carriera di Kerry Russell
Precedenti posizioni note di Kerry Russell
Società | Posizione | Inizio | Fine |
---|---|---|---|
TERNS PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/06/2022 | 01/05/2023 |
Corporate Officer/Principal | 01/05/2023 | 01/07/2023 | |
DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/06/2020 | 01/05/2022 |
DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
ADICET BIO, INC. | Corporate Officer/Principal | 12/06/2018 | - |
Formazione di Kerry Russell
Rice University | Undergraduate Degree |
The University of Texas at Austin | Doctorate Degree |
The University of Texas Health Science Center at Houston | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 7 |
Posizioni
Corporate Officer/Principal | 4 |
Doctorate Degree | 2 |
Undergraduate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
TERNS PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 2 |
---|---|
resTORbio, Inc.
![]() resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Dicerna Pharmaceuticals, Inc.
![]() Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
- Borsa valori
- Insiders
- Kerry Russell
- Esperienza